stockrow
Saturday 7 November 2026
Export IBIO’s income statement to Excel — free account
iBio, Inc.
IBIO Healthcare Biotechnology
iBio, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $100,000.00, down 75.0% from fiscal 2025.
- Revenue
- +100.0%
- EPS
- +80.5%
- Free cash flow
- −35.3%
Quarter to June 2026, against a year earlier
0.75
0.02
+2.74%
Follow IBIO
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | 0.00 |
+8 more quarters Free account |
P/S ratio |
— | — | — | 65.15 | |
P/FCF ratio |
— | — | — | 0.00 | |
P/Operating CF |
— | — | — | (7.76) | |
P/B ratio |
— | — | — | 0.78 | |
Price to Tangible BV |
— | — | — | 0.89 | |
EV/Sales |
— | — | — | (6.26) | |
EV/EBITDA |
— | — | — | 0.22 | |
EV/Operating CF |
— | — | — | 0.25 | |
EV/FCF |
— | — | — | 0.24 | |
Quick Ratio |
7.59 | 11.50 | 8.93 | 8.21 | |
Current Ratio |
7.85 | 11.88 | 9.04 | 8.39 | |
Net Debt/EBITDA |
7.89 | 9.14 | 5.68 | 8.61 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 1.13% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.01 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.02 | |
Operating CF/Net income |
0.59 | 0.79 | 0.58 | 0.99 | |
Capex/Depreciation |
(0.09) | (0.06) | (3.19) | (0.11) | |
Interest Coverage |
247.39 | (380.23) | (230.37) | (165.31) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 3,550.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 2,501.00% | |
Intangible Assets out of Total Assets |
0.02 | 0.02 | 0.07 | 0.11 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 323.00% | |
Graham Net Nets |
— | — | — | 0.97 | |
Graham Number |
— | — | — | 0.00 | |
Earnings Yield |
— | — | — | (173.41%) | |
Free Cash Flow Yield |
— | — | — | (40.33%) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.06) | (0.05) | (0.05) | (0.11) | |
Capex per Share |
0.00 | 0.00 | (0.01) | 0.00 | |
Free Cash Flow per Share |
(0.06) | (0.05) | (0.06) | (0.11) | |
Cash per Share |
0.85 | 0.63 | 0.53 | 0.94 | |
Shareholders Equity per Share |
0.82 | 0.65 | 0.57 | 1.06 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.82 | 0.65 | 0.57 | 1.06 | |
Free Cash Flow |
(6.25) | (6.09) | (5.76) | (5.70) | |
Working Capital |
80.48 | 70.75 | 47.47 | 44.72 | |
Capital Expenditures |
(0.02) | (0.01) | (0.52) | (0.03) | |
Net Current Asset Value |
78.82 | 68.95 | 45.54 | 42.66 | |
EV/EBIT |
— | — | — | 0.21 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.32 | |
Price to Operating Income |
— | — | — | 0.00 | |
| Other line items | |||||
Average Receivables |
0.91 | — | — | 7.08 | |
Average Payables |
3.31 | 2.26 | 1.63 | 1.84 | |
Average Assets |
61.15 | 52.47 | 43.05 | 44.34 | |
Average Common Equity |
50.30 | 44.46 | 35.23 | 36.90 |
Columns are period end dates · fundamentals updated 26 Oct 2026